Impact of a whole-food plant-based diet (WFPBD) on weight and metabo-inflammation in men with prostate cancer (PC) receiving androgen deprivation therapy (ADT): A multi-center randomized control trial.
Abstract
5098 Background: Obesity promotes a chronic inflammatory state associated with PC progression. ADT can cause weight gain, accumulation of body fat, insulin resistance and increased risk of diabetes and cardiovascular disease. A WFPBD promotes weight loss, decreases inflammation, and shifts the gut microbiome to promote insulin sensitivity. We hypothesized that a WFPBD and behavioral intervention will promote weight loss and a reduction in adiposity in overweight/obese patients with PC on ADT. Methods: Pts with PC with BMI ≥ 27 receiving ADT with an LHRH/GnRH analogue for >24 wks pre-study (+ AR pathway inhibitor allowed if stable dose for >3 mos) with plan >26 more wks were eligible. 60 patients were randomized 1:1. WFPBD group: 12 prepared and home delivered WFPBD meals per wks 1-4, 6 meals wks 5-8 and coaching to assist in self-prepping plant-based meals (wks 9-26); Control group: counseling on a general healthful diet from a Registered Dietician weekly for 8 wks, then monthly (wks 9-26). Baseline and serial measurements (pre-intervention, wks 4, 8 and 26): weight, body composition assessment via dual energy x-ray absorptiometry (DXA), and biomarkers of inflammation and metabolism were collected. Primary endpoint was weight loss at 4 weeks (with an 80% power to detect an effect size 0.74 standard deviations with a 2-sided significance level of 0.05 using a two-sample t-test). Secondary objectives were change in body composition, biomarkers of metabolic disorders and cardiovascular risk and quality of life measurements. Results: 60 pts were randomized (31 control, 29 WFPBD). Median age was 73; Race: 65% white, 28% Black, 2% Asian, 5% other/unknown; Median baseline weight 98 kg; No difference in baseline HbA1c or lipid profile between groups. Mean weight loss (kg) at 4, 8 and 26 wks: WFPBD: 3.9, 5.3 and 6.1 kg; Control 1.3, 1.6, 2.1 kg, respectively (each timepoint pair p<0.001). DXA measured BMI change at 4 and 26 wks: WFPBD: -1.1 and -1.93 kg/m 2 , Control: 0.35 and 0.25 kg/m 2 (each timepoint pair p<0.001). DXA measured mean lean (LM), fat (FM) and total mass (TM) showed declines at 4 wks in WFPBD versus Control (LM -2.4 vs -0.64 (p<0.001); FM -1.3 vs -0.35 (p=0.023); TM -3.61 vs -0.88 (p<0.001), whereas at 26 weeks only FM and TM remained significantly less (LM -2.2 vs -1.4 (p=0.143); FM -5.3 vs -0.8 (p=0.001); TM -6.7 vs -2.2 (p<0.001). No significant differences were seen in HbA1c or lipid profiles at 6 mos. Conclusions: Compared with nutritional counseling, obese men with PC on ADT subjected to a home-delivered WFPBD for 2 mos and behavioral coaching experienced significantly greater weight loss, BMI reduction and decreases in total and fat mass that persisted for 6 months. Biomarkers of metabo-inflammation, insulin levels, fecal microbiota and metabolites, and serum for metabolomics collected are undergoing analyses. Clinical trial information: NCT05471414 .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (16)
Nicole Jacobs
Weill Cornell Medicine, New York, NY
Katie Hootman
Victoria Fischer
Queens College, Queens, NY
Brooke Greenfield
Weill Cornell Medicine, New Rochelle, NY
Abdul Baseet Arham
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY
Nadja Pinnavaia
Plantable, New York, NY
Emily Peck
Cook Unity, New York, NY
Diamanise M. Sidberry
Weill Cornell Medicine, New York, NY
Jenna Robander
Weill Cornell Medicine, New York, NY
Ana M. Molina
Weill Cornell Medicine, New York, NY
Cora N. Sternberg
Andrew J. Armstrong, MD, ScM, FACP, Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University, Durham, NC; Arun A. Azad, MBBS, PhD; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia; Fred Saad, MD, University of Montreal Hospital Center, Montreal, QC, Canada; Maha Hussain, MD, FACP, FASCO, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Taro Iguchi, MD, PhD, Department of Urology, Kanazawa Medical University, Ishikawa, Japan; Arnulf Stenzl, MD, Department of Urology, University of Tübingen, Tübingen, Germany; and Cora N. Sternberg, MD, FACP, Englander Institute for Precision Medicine, Meyer Cancer Center, Weill Cornell Medicine, New York, NY
Scott T. Tagawa
Weill Cornell Medical Center, NewYork Presbyterian Hospital, New York, NY
Zhengming Chen
Mark N. Stein
Columbia University Medical Center, New York, NY
Channing Judith Paller
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, MD
David M. Nanus
Weill Cornell Medical Center, NewYork-Presbyterian Hospital, New York, NY